Adamas merger investigation: halper sadeh llp announces investigation into whether the sale of adamas pharmaceuticals, inc. is fair to shareholders; investors are encouraged to contact the firm – adms

New york--(business wire)--halper sadeh llp, a global investor rights law firm, is investigating whether the sale of adamas pharmaceuticals, inc. (nasdaq: adms) to supernus pharmaceuticals, inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to adamas shareholders. halper sadeh encourages adamas shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halpe
ADMS Ratings Summary
ADMS Quant Ranking